Endo International PLC (NASDAQ:ENDP) Bond Prices Rise 1.2%

An issue of Endo International PLC (NASDAQ:ENDP) debt rose 1.2% against its face value during trading on Tuesday. The high-yield debt issue has a 7.75% coupon and will mature on January 15, 2022. The debt is now trading at $99.19. Price changes in a company’s debt in credit markets sometimes predict parallel changes in its share price.

A number of brokerages have commented on ENDP. William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research report on Wednesday, June 14th. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $22.00 to $15.00 in a research report on Friday, June 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $9.00 price objective (down previously from $15.00) on shares of Endo International PLC in a research report on Wednesday, August 9th. Vetr upgraded Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price objective for the company in a research report on Wednesday, May 17th. Finally, Morgan Stanley reduced their price objective on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, August 10th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $14.75.

Shares of Endo International PLC (ENDP) opened at 8.72 on Friday. The stock has a 50 day moving average price of $10.47 and a 200 day moving average price of $11.43. Endo International PLC has a 1-year low of $7.41 and a 1-year high of $24.93. The firm’s market capitalization is $1.95 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same quarter last year, the firm earned $0.86 EPS. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities research analysts anticipate that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

In other news, CEO Paul Campanelli bought 6,500 shares of the company’s stock in a transaction on Monday, August 14th. The shares were purchased at an average price of $7.71 per share, with a total value of $50,115.00. Following the transaction, the chief executive officer now directly owns 213,620 shares in the company, valued at $1,647,010.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were purchased at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. Gamco Investors INC. ET AL boosted its position in Endo International PLC by 25.1% in the first quarter. Gamco Investors INC. ET AL now owns 59,400 shares of the company’s stock valued at $663,000 after buying an additional 11,900 shares in the last quarter. Icon Advisers Inc. Co. boosted its position in Endo International PLC by 314.4% in the first quarter. Icon Advisers Inc. Co. now owns 74,600 shares of the company’s stock valued at $833,000 after buying an additional 56,600 shares in the last quarter. Comerica Bank boosted its position in Endo International PLC by 233.7% in the first quarter. Comerica Bank now owns 153,881 shares of the company’s stock valued at $1,736,000 after buying an additional 107,761 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. Finally, Point View Wealth Management Inc. boosted its position in Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares in the last quarter. 92.27% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.com-unik.info/2017/08/19/endo-international-plc-nasdaqendp-bonds-rise-1-2-during-trading-updated.html.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

What are top analysts saying about Endo International PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit